Targeting sensitized nerves to treat chronic & debilitating neurogenic disorders
Afferent Pharmaceuticals is a clinical-stage biotechnology company and leader in the development of novel drugs for the treatment of a range of neurogenic disorders. These disorders affect millions of patients who suffer from chronic respiratory and urologic sensory pathologies, as well as chronic pain and cardiovascular disorders, and who have limited, if any, treatment options.
In June 2016, Merck and Afferent signed a definitive agreement under which Merck will acquire Afferent for up to $1.25 billion.
Year Invested: 2009
Location: San Mateo, Calif.